Tags

Type your tag names separated by a space and hit enter

Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method.
BJOG. 2008 May; 115(6):773-9.BJOG

Abstract

OBJECTIVE

To evaluate impact of different postmenopausal hormone therapy (HT) regimens and raloxifene on mammographic breast density.

DESIGN

Open, randomised, comparative clinical trial.

SETTING

Women were recruited through local newspapers and posters. They were examined at the Departments of Haematology, Gynaecology, and Radiology in a University Hospital.

POPULATION

A total of 202 healthy postmenopausal women between the age of 45 and 65 years.

METHODS

Women were randomly assigned to receive daily treatment for 12 weeks with tablets containing low-dose HT containing 1 mg 17 beta-estradiol + 0.5 mg norethisterone acetate (NETA) (n = 50), conventional-dose HT containing 2 mg 17 beta-estradiol and 1 mg NETA (n = 50), 2.5 mg tibolone (n = 51), or 60 mg raloxifene (n = 51). Mammographic density was determined at baseline and after 12 weeks by an automated technique in full-field digital mammograms.

MAIN OUTCOME MEASURES

Mammographic density was expressed as volumetric breast density estimations.

RESULTS

Mammographic breast density increased significantly and to a similar degree in both the conventional- and low-dose HT groups. A small reduction in mammographic breast density was seen in the raloxifene group, whereas those allocated to tibolone treatment only showed minor changes.

CONCLUSIONS

Our findings demonstrated a significant difference in impact on mammographic breast density between the regimens. Although these results indicate a differential effect of these regimens on breast tissue, the relation to breast cancer risk remains unresolved.

Authors+Show Affiliations

Department of Haematology and Faculty Division, Ullevål University Hospital Trust, Oslo, Norway. a.l.eilertsen@medisin.uio.noNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18355366

Citation

Eilertsen, A L., et al. "Differential Impact of Conventional and Low-dose Oral Hormone Therapy, Tibolone and Raloxifene On Mammographic Breast Density, Assessed By an Automated Quantitative Method." BJOG : an International Journal of Obstetrics and Gynaecology, vol. 115, no. 6, 2008, pp. 773-9.
Eilertsen AL, Karssemeijer N, Skaane P, et al. Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. BJOG. 2008;115(6):773-9.
Eilertsen, A. L., Karssemeijer, N., Skaane, P., Qvigstad, E., & Sandset, P. M. (2008). Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. BJOG : an International Journal of Obstetrics and Gynaecology, 115(6), 773-9. https://doi.org/10.1111/j.1471-0528.2008.01690.x
Eilertsen AL, et al. Differential Impact of Conventional and Low-dose Oral Hormone Therapy, Tibolone and Raloxifene On Mammographic Breast Density, Assessed By an Automated Quantitative Method. BJOG. 2008;115(6):773-9. PubMed PMID: 18355366.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. AU - Eilertsen,A L, AU - Karssemeijer,N, AU - Skaane,P, AU - Qvigstad,E, AU - Sandset,P M, Y1 - 2008/03/19/ PY - 2008/3/22/pubmed PY - 2008/6/7/medline PY - 2008/3/22/entrez SP - 773 EP - 9 JF - BJOG : an international journal of obstetrics and gynaecology JO - BJOG VL - 115 IS - 6 N2 - OBJECTIVE: To evaluate impact of different postmenopausal hormone therapy (HT) regimens and raloxifene on mammographic breast density. DESIGN: Open, randomised, comparative clinical trial. SETTING: Women were recruited through local newspapers and posters. They were examined at the Departments of Haematology, Gynaecology, and Radiology in a University Hospital. POPULATION: A total of 202 healthy postmenopausal women between the age of 45 and 65 years. METHODS: Women were randomly assigned to receive daily treatment for 12 weeks with tablets containing low-dose HT containing 1 mg 17 beta-estradiol + 0.5 mg norethisterone acetate (NETA) (n = 50), conventional-dose HT containing 2 mg 17 beta-estradiol and 1 mg NETA (n = 50), 2.5 mg tibolone (n = 51), or 60 mg raloxifene (n = 51). Mammographic density was determined at baseline and after 12 weeks by an automated technique in full-field digital mammograms. MAIN OUTCOME MEASURES: Mammographic density was expressed as volumetric breast density estimations. RESULTS: Mammographic breast density increased significantly and to a similar degree in both the conventional- and low-dose HT groups. A small reduction in mammographic breast density was seen in the raloxifene group, whereas those allocated to tibolone treatment only showed minor changes. CONCLUSIONS: Our findings demonstrated a significant difference in impact on mammographic breast density between the regimens. Although these results indicate a differential effect of these regimens on breast tissue, the relation to breast cancer risk remains unresolved. SN - 1471-0528 UR - https://www.unboundmedicine.com/medline/citation/18355366/Differential_impact_of_conventional_and_low_dose_oral_hormone_therapy_tibolone_and_raloxifene_on_mammographic_breast_density_assessed_by_an_automated_quantitative_method_ L2 - https://doi.org/10.1111/j.1471-0528.2008.01690.x DB - PRIME DP - Unbound Medicine ER -